^
    2ms
    BGB-LC-202: Efficacy, Safety, and Pharmacodynamics of Tislelizumab Monotherapy and Multiple Tislelizumab-based Immunotherapy Combinations in Participants With Resectable Non-Small Cell Lung Cancer (clinicaltrials.gov)
    P2, N=121, Active, not recruiting, BeiGene | Recruiting --> Active, not recruiting
    Enrollment closed
    |
    PD-L1 (Programmed death ligand 1)
    |
    PD-L1 expression
    |
    cisplatin • carboplatin • paclitaxel • Tevimbra (tislelizumab-jsgr) • pemetrexed • ociperlimab (BGB-A1217) • LBL-007
    2ms
    Treatment of Relapsed or Refractory Diffuse Large B Cell Lymphoma With Ociperlimab (BGB A1217) in Combination With Tislelizumab (BGB A317) or Rituximab (clinicaltrials.gov)
    P1/2, N=53, Completed, BeiGene | Active, not recruiting --> Completed | Trial completion date: Feb 2025 --> Aug 2024
    Trial completion • Trial completion date
    |
    PD-L1 (Programmed death ligand 1)
    |
    Rituxan (rituximab) • Tevimbra (tislelizumab-jsgr) • ociperlimab (BGB-A1217)
    3ms
    AdvanTIG-205: Ociperlimab with Tislelizumab and Chemotherapy in Participants with Untreated Metastatic Non-Small Cell Lung Cancer (clinicaltrials.gov)
    P2, N=272, Completed, BeiGene | Active, not recruiting --> Completed
    Trial completion
    |
    PD-L1 (Programmed death ligand 1)
    |
    Tevimbra (tislelizumab-jsgr) • ociperlimab (BGB-A1217)
    3ms
    AdvanTIG-302: A Study of Ociperlimab With Tislelizumab Compared to Pembrolizumab in Participants With Untreated Lung Cancer (clinicaltrials.gov)
    P3, N=662, Active, not recruiting, BeiGene | Trial completion date: Oct 2026 --> Feb 2027 | Trial primary completion date: Apr 2026 --> Oct 2026
    Trial completion date • Trial primary completion date • Combination therapy • Metastases
    |
    PD-L1 (Programmed death ligand 1)
    |
    PD-L1 expression
    |
    Keytruda (pembrolizumab) • Tevimbra (tislelizumab-jsgr) • ociperlimab (BGB-A1217)
    4ms
    AdvanTIG-105: Study of Ociperlimab (BGB-A1217) in Combination with Tislelizumab in Advanced Solid Tumors (clinicaltrials.gov)
    P1, N=449, Completed, BeiGene | Active, not recruiting --> Completed
    Trial completion • Combination therapy • Metastases
    |
    PD-L1 (Programmed death ligand 1)
    |
    PD-L1 expression
    |
    Tevimbra (tislelizumab-jsgr) • ociperlimab (BGB-A1217)
    6ms
    Treatment of Relapsed or Refractory Diffuse Large B Cell Lymphoma With Ociperlimab (BGB A1217) in Combination With Tislelizumab (BGB A317) or Rituximab (clinicaltrials.gov)
    P1/2, N=53, Active, not recruiting, BeiGene | N=80 --> 53 | Recruiting --> Active, not recruiting
    Enrollment closed • Enrollment change • Trial completion date • Trial primary completion date • Combination therapy
    |
    PD-L1 (Programmed death ligand 1)
    |
    Rituxan (rituximab) • Tevimbra (tislelizumab-jsgr) • ociperlimab (BGB-A1217)
    7ms
    AdvanTIG-302: A Study of Ociperlimab With Tislelizumab Compared to Pembrolizumab in Participants With Untreated Lung Cancer (clinicaltrials.gov)
    P3, N=662, Active, not recruiting, BeiGene | Recruiting --> Active, not recruiting
    Enrollment closed • Combination therapy • Metastases
    |
    PD-L1 (Programmed death ligand 1)
    |
    Keytruda (pembrolizumab) • Tevimbra (tislelizumab-jsgr) • ociperlimab (BGB-A1217)
    7ms
    AdvanTIG-205: Ociperlimab With Tislelizumab and Chemotherapy in Participants With Untreated Metastatic Non-Small Cell Lung Cancer (clinicaltrials.gov)
    P2, N=272, Active, not recruiting, BeiGene | Trial primary completion date: Jul 2024 --> Oct 2024
    Trial primary completion date
    |
    PD-L1 (Programmed death ligand 1)
    |
    Tevimbra (tislelizumab-jsgr) • ociperlimab (BGB-A1217)
    7ms
    BGB-A317-290-LTE1: Study of Tislelizumab, Pamiparib, and Other Investigational Agents in Participants With Advanced Malignancies (clinicaltrials.gov)
    P3, N=300, Enrolling by invitation, BeiGene | Trial completion date: Aug 2024 --> Dec 2026 | Trial primary completion date: Aug 2024 --> Dec 2026
    Trial completion date • Trial primary completion date • Metastases
    |
    temozolomide • Lenvima (lenvatinib) • Tevimbra (tislelizumab-jsgr) • Fruzaqla (fruquintinib) • Partruvix (pamiparib) • Ziihera (zanidatamab-hrii) • Avzivi (bevacizumab-tnjn) • ociperlimab (BGB-A1217) • sitravatinib (MGCD516) • BGB-15025 • BGB-A445 • LBL-007 • surzebiclimab (BGB-A425)
    9ms
    AdvanTIG-203: Anti-PD-1 Monoclonal Antibody Tislelizumab (BGB-A317) Combined With or Without Anti-TIGIT Monoclonal Antibody Ociperlimab (BGB-A1217) in Participants With Recurrent or Metastatic Esophageal Squamous Cell Carcinoma (clinicaltrials.gov)
    P2, N=125, Completed, BeiGene | Active, not recruiting --> Completed
    Trial completion
    |
    PD-L1 (Programmed death ligand 1)
    |
    Tevimbra (tislelizumab-jsgr) • ociperlimab (BGB-A1217)
    10ms
    Structural insights into the unique pH-responsive characteristics of the anti-TIGIT therapeutic antibody Ociperlimab. (PubMed, Structure)
    TIGIT is mainly expressed on T cells and is an inhibitory checkpoint receptor that binds to its ligand PVR in the tumor microenvironment. In contrast, Tiragolumab does not show an acidic pH-dependent binding enhancement. Our results provide valuable information that could help to improve the efficacy of therapeutic antibodies for cancer treatment.
    Journal
    |
    TIGIT (T Cell Immunoreceptor With Ig And ITIM Domains 2)
    |
    ociperlimab (BGB-A1217) • tiragolumab (RG6058)
    10ms
    Exploration of potential biomarkers correlated with efficacy of ociperlimab (anti-TIGIT) plus tislelizumab (anti-PD-1) in 1L PD-L1+ non-small cell lung cancer (NSCLC) (AACR 2024)
    Anti-TIGIT MOA-related genes and signatures correlated with efficacy in ociperlimab + tislelizumab-treated 1L PD-L1+ NSCLC. Combining anti-TIGIT MOA-related factors with PD-L1 expression identified a subgroup of patients with improved efficacy.Table. Efficacy Analyses in Patient SubgroupsCutoff: aTop 1/3; bMedian; cTC≥25%
    Clinical • PD(L)-1 Biomarker • IO biomarker
    |
    PD-L1 (Programmed death ligand 1) • TIGIT (T Cell Immunoreceptor With Ig And ITIM Domains 2) • CCR8 (C-C Motif Chemokine Receptor 8) • CD226 (CD226 Molecule)
    |
    PD-L1 expression • TIGIT expression
    |
    VENTANA PD-L1 (SP263) Assay
    |
    Tevimbra (tislelizumab-jsgr) • ociperlimab (BGB-A1217)
    10ms
    AdvanTIG-302: A Study of Ociperlimab With Tislelizumab Compared to Pembrolizumab in Participants With Untreated Lung Cancer (clinicaltrials.gov)
    P3, N=660, Recruiting, BeiGene | Trial completion date: May 2025 --> Oct 2026 | Trial primary completion date: Jan 2025 --> Apr 2026
    Trial completion date • Trial primary completion date • Combination therapy • Metastases
    |
    PD-L1 (Programmed death ligand 1)
    |
    PD-L1 expression
    |
    Keytruda (pembrolizumab) • Tevimbra (tislelizumab-jsgr) • ociperlimab (BGB-A1217)
    10ms
    AdvanTIG-105: Study of Ociperlimab (BGB-A1217) in Combination With Tislelizumab in Advanced Solid Tumors (clinicaltrials.gov)
    P1, N=449, Active, not recruiting, BeiGene | Recruiting --> Active, not recruiting | Trial primary completion date: May 2024 --> Aug 2024
    Enrollment closed • Trial primary completion date • Combination therapy • Metastases
    |
    PD-L1 (Programmed death ligand 1)
    |
    PD-L1 expression
    |
    cisplatin • carboplatin • Tevimbra (tislelizumab-jsgr) • capecitabine • albumin-bound paclitaxel • pemetrexed • oxaliplatin • etoposide IV • ociperlimab (BGB-A1217)
    10ms
    AdvanTIG-206: A Study Investigating the Efficacy and Safety of Ociperlimab and Tislelizumab and BAT1706 Combinations in Patients With Advanced HCC (clinicaltrials.gov)
    P2, N=94, Completed, BeiGene | Active, not recruiting --> Completed
    Trial completion
    |
    PD-L1 (Programmed death ligand 1)
    |
    PD-L1 expression
    |
    Tevimbra (tislelizumab-jsgr) • Avzivi (bevacizumab-tnjn) • ociperlimab (BGB-A1217)
    11ms
    BGB-A317-A1217-301: A Study to Compare Ociperlimab Plus Tislelizumab Versus Durvalumab Following Concurrent Chemoradiotherapy (cCRT) in Patients With Stage III Unresectable Non-Small Cell Lung Cancer (clinicaltrials.gov)
    P3, N=63, Terminated, BeiGene | Trial completion date: Jul 2027 --> Oct 2023 | Active, not recruiting --> Terminated | Trial primary completion date: Feb 2027 --> Oct 2023; This decision was conducted by the sponsor and not driven by safety concerns as no new safety signals have been observed in the ociperlimab program.
    Trial completion date • Trial termination • Trial primary completion date • Metastases
    |
    Imfinzi (durvalumab) • Tevimbra (tislelizumab-jsgr) • ociperlimab (BGB-A1217)
    12ms
    AdvanTIG-302: A Study of Ociperlimab With Tislelizumab Compared to Pembrolizumab in Participants With Untreated Lung Cancer (clinicaltrials.gov)
    P3, N=660, Recruiting, BeiGene
    Trial completion date • Trial primary completion date • Combination therapy • Metastases
    |
    PD-L1 (Programmed death ligand 1)
    |
    PD-L1 expression
    |
    Keytruda (pembrolizumab) • Tevimbra (tislelizumab-jsgr) • ociperlimab (BGB-A1217)
    1year
    AdvanTIG-105: Study of Ociperlimab (BGB-A1217) in Combination With Tislelizumab in Advanced Solid Tumors (clinicaltrials.gov)
    P1, N=542, Recruiting, BeiGene
    Trial completion date • Trial primary completion date • Combination therapy • Metastases
    |
    PD-L1 (Programmed death ligand 1)
    |
    PD-L1 expression
    |
    cisplatin • carboplatin • Tevimbra (tislelizumab-jsgr) • capecitabine • albumin-bound paclitaxel • pemetrexed • oxaliplatin • etoposide IV • ociperlimab (BGB-A1217)
    1year
    BGB-LC-202: Efficacy, Safety, and Pharmacodynamics of Tislelizumab Monotherapy and Multiple Tislelizumab-based Immunotherapy Combinations in Participants With Resectable Non-Small Cell Lung Cancer (clinicaltrials.gov)
    P2, N=120, Recruiting, BeiGene | N=90 --> 120
    Enrollment change • Trial completion date • Trial primary completion date
    |
    PD-L1 (Programmed death ligand 1)
    |
    PD-L1 expression
    |
    cisplatin • carboplatin • paclitaxel • Tevimbra (tislelizumab-jsgr) • pemetrexed • ociperlimab (BGB-A1217) • LBL-007
    1year
    Treatment of Relapsed or Refractory Diffuse Large B Cell Lymphoma With Ociperlimab (BGB A1217) in Combination With Tislelizumab (BGB A317) or Rituximab (clinicaltrials.gov)
    P1/2, N=80, Recruiting, BeiGene | Phase classification: P1b/2 --> P1/2
    Phase classification • Combination therapy
    |
    PD-L1 (Programmed death ligand 1)
    |
    Rituxan (rituximab) • Tevimbra (tislelizumab-jsgr) • ociperlimab (BGB-A1217)
    1year
    BGB-A317-A1217-202: AdvanTIG-202: Anti-PD-1 Monoclonal Antibody Tislelizumab (BGB-A317) Combined With or Without Anti-TIGIT Monoclonal Antibody Ociperlimab (BGB-A1217) in Participants With Previously Treated Recurrent or Metastatic Cervical Cancer (clinicaltrials.gov)
    P2, N=178, Completed, BeiGene | Active, not recruiting --> Completed
    Trial completion • Metastases
    |
    PD-L1 (Programmed death ligand 1)
    |
    PD-L1 expression
    |
    Tevimbra (tislelizumab-jsgr) • ociperlimab (BGB-A1217)
    1year
    AdvanTIG-105: a phase I dose escalation study of the anti-TIGIT monoclonal antibody ociperlimab in combination with tislelizumab in patients with advanced solid tumors. (PubMed, J Immunother Cancer)
    Ociperlimab plus tislelizumab was well tolerated in patients with advanced solid tumors, and preliminary antitumor activity was observed with 450 mg, 900 mg, and 1800 mg ociperlimab. Phase II/III trials of ociperlimab 900 mg plus tislelizumab 200 mg Q3W are underway in a range of solid tumors.
    P1 data • Journal • Combination therapy • PD(L)-1 Biomarker • IO biomarker • Metastases
    |
    TIGIT (T Cell Immunoreceptor With Ig And ITIM Domains 2)
    |
    Tevimbra (tislelizumab-jsgr) • ociperlimab (BGB-A1217)
    1year
    Exploration of Potential Biomarkers Correlated with Efficacy of Ociperlimab (OCI) plus Tislelizumab (TIS) in 1L PD-L1+ Non-Small Cell Lung Cancer (NSCLC) (ESMO-IO 2023)
    No abstract available
    Clinical • PD(L)-1 Biomarker • IO biomarker
    |
    PD-L1 (Programmed death ligand 1)
    |
    Tevimbra (tislelizumab-jsgr) • ociperlimab (BGB-A1217)
    over1year
    AdvanTIG-203: Anti-PD-1 Monoclonal Antibody Tislelizumab (BGB-A317) Combined With or Without Anti-TIGIT Monoclonal Antibody Ociperlimab (BGB-A1217) in Participants With Recurrent or Metastatic Esophageal Squamous Cell Carcinoma (clinicaltrials.gov)
    P2, N=125, Active, not recruiting, BeiGene | Recruiting --> Active, not recruiting | Trial primary completion date: Nov 2023 --> Feb 2023
    Enrollment closed • Trial primary completion date • Metastases
    |
    PD-L1 (Programmed death ligand 1)
    |
    Tevimbra (tislelizumab-jsgr) • ociperlimab (BGB-A1217)
    over1year
    AdvanTIG-105: Phase 1b Dose-Expansion Study of Ociperlimab + Tislelizumab in Patients With Checkpoint Inhibitor (CPI)-Experienced Advanced Non-Small Cell Lung Cancer (NSCLC) (COSA 2023)
    Ociperlimab 900mg + tislelizumab 200mg was generally well-tolerated and showed preliminary antitumor activity in patients with locally advanced/metastatic CPI-experienced NSCLC.
    Clinical • P1 data • Checkpoint inhibition • Metastases
    |
    TIGIT (T Cell Immunoreceptor With Ig And ITIM Domains 2)
    |
    Tevimbra (tislelizumab-jsgr) • ociperlimab (BGB-A1217)
    over1year
    AdvanTIG-206: A Study Investigating the Efficacy and Safety of Ociperlimab and Tislelizumab and BAT1706 Combinations in Patients With Advanced HCC (clinicaltrials.gov)
    P2, N=90, Active, not recruiting, BeiGene | Trial completion date: Aug 2023 --> Mar 2024 | Trial primary completion date: Aug 2023 --> Mar 2024
    Trial completion date • Trial primary completion date • Combination therapy • Metastases
    |
    PD-L1 (Programmed death ligand 1)
    |
    PD-L1 expression
    |
    Tevimbra (tislelizumab-jsgr) • Avzivi (bevacizumab-tnjn) • ociperlimab (BGB-A1217)
    over1year
    AdvanTIG-205: Ociperlimab With Tislelizumab and Chemotherapy in Patients With Untreated Metastatic Non-Small Cell Lung Cancer (clinicaltrials.gov)
    P2, N=272, Active, not recruiting, BeiGene | Recruiting --> Active, not recruiting | Trial primary completion date: Mar 2024 --> Jul 2024
    Enrollment closed • Trial primary completion date • Metastases
    |
    PD-L1 (Programmed death ligand 1)
    |
    Tevimbra (tislelizumab-jsgr) • ociperlimab (BGB-A1217)
    over1year
    BGB-A317-A1217-301: A Study to Compare Ociperlimab Plus Tislelizumab Versus Durvalumab Following Concurrent Chemoradiotherapy (cCRT) in Patients With Stage III Unresectable Non-Small Cell Lung Cancer (clinicaltrials.gov)
    P3, N=63, Active, not recruiting, BeiGene | Recruiting --> Active, not recruiting | N=700 --> 63
    Enrollment closed • Enrollment change • IO biomarker • Metastases
    |
    PD-L1 (Programmed death ligand 1) • TIGIT (T Cell Immunoreceptor With Ig And ITIM Domains 2)
    |
    PD-L1 expression • TIGIT expression
    |
    Imfinzi (durvalumab) • Tevimbra (tislelizumab-jsgr) • ociperlimab (BGB-A1217)
    over1year
    Treatment of Relapsed or Refractory Diffuse Large B Cell Lymphoma With Ociperlimab (BGB A1217) in Combination With Tislelizumab (BGB A317) or Rituximab (clinicaltrials.gov)
    P1b/2, N=80, Recruiting, BeiGene | Trial completion date: Oct 2024 --> Feb 2025 | Trial primary completion date: Aug 2024 --> Nov 2024
    Trial completion date • Trial primary completion date • Combination therapy
    |
    PD-L1 (Programmed death ligand 1)
    |
    Rituxan (rituximab) • Tevimbra (tislelizumab-jsgr) • ociperlimab (BGB-A1217)
    over1year
    Advantig-105: Phase Ib dose-expansion study of ociperlimab (OCI) + tislelizumab (TIS) with chemotherapy (CT) in patients (pts) with metastatic oesophageal squamous cell carcinoma (ESCC) and oesophageal adenocarcinoma (EAC) (ESMO 2023)
    Pts received the RP2D of OCI + TIS with cisplatin + 5-fluorouracil/paclitaxel until disease progression, intolerable toxicity, or consent withdrawal. C7 had too few pts for biomarker subgroup analysis. Table: 1533P Efficacy and Safety Summary Conclusions These results demonstrate that OCI 900 mg + TIS 200 mg + CT had a safety profile consistent with previous reports and showed encouraging antitumor activity in pts with stage IV ESCC and EAC.
    Clinical • P1 data • PD(L)-1 Biomarker • IO biomarker • Metastases
    |
    PD-L1 (Programmed death ligand 1) • TIGIT (T Cell Immunoreceptor With Ig And ITIM Domains 2)
    |
    PD-L1 expression
    |
    cisplatin • paclitaxel • 5-fluorouracil • Tevimbra (tislelizumab-jsgr) • ociperlimab (BGB-A1217)
    over1year
    AdvanTIG-202: Phase II randomized, multicenter, open-label study of tislelizumab (TIS) with or without ociperlimab (OCI) in patients (pts) with previously treated recurrent/metastatic (R/M) cervical cancer (CC) (ESMO 2023)
    DoR, duration of response; IRC, independent review committee; m, median; mo, months; NE, not estimable; ORR, objective response rate; OS, overall survival; PFS, progression-free survival. . Conclusions OCI + TIS showed promising antitumor activity and durable responses, regardless of PD-L1 expression, and was well tolerated in pts with previously treated R/M CC.
    Clinical • P2 data • PD(L)-1 Biomarker • IO biomarker • Metastases
    |
    PD-L1 (Programmed death ligand 1) • TIGIT (T Cell Immunoreceptor With Ig And ITIM Domains 2)
    |
    PD-L1 expression
    |
    Tevimbra (tislelizumab-jsgr) • ociperlimab (BGB-A1217)
    over1year
    AdvanTIG-203: Phase II randomized, multicenter study of ociperlimab (OCI) + tislelizumab (TIS) in patients (pts) with unresectable, locally advanced, recurrent/metastatic esophageal squamous cell carcinoma (ESCC) and programmed cell death-ligand 1 (PD-L1) positivity (ESMO 2023)
    Table: 1020MO Efficacy O+T (n=62) P+T (n=63) ORRa, % (95% CI) INV b 30.6 (19.6, 43.7) 20.6 (11.5, 32.7) P c,d =0.2114 IRC e 32.3 (20.9, 45.3) 25.4 (15.3, 37.9) P c,d =0.4209 OS e,f (months), median (95% CI) 10.1 (7.1, NE) 9.3 (6.0, NE) HRc (95% CI): 0.93 (0.55, 1.58) P c,g =0.3977 PFS e (months), median (95% CI) INV 3.4 (1.8, 5.1) 3.5 (1.9, 4.1) HRc (95% CI): 0.93 (0.61, 1.43) IRC 3.6 (2.7, 5.1) 2.8 (1.9, 6.9) HRc (95% CI): 1.01 (0.64, 1.59) Median follow-up was 7 months. IRC, independent review committee; NE, not estimable aConfirmed per RECIST v1.1bPrimary endpoint cStratified d2-sided; by Cochran-Mantel-Haenszel method eSecondary endpoint fStill immature (event rate 45.6%) g1-sided; by log-rank test Conclusions In 2L therapy of advanced ESCC pts with PD-L1 TAP ≥10%, O+T showed tolerable safety profile and trend toward better ORR, but similar PFS vs. P+T.
    Clinical • P2 data • Metastases
    |
    PD-L1 (Programmed death ligand 1) • TIGIT (T Cell Immunoreceptor With Ig And ITIM Domains 2)
    |
    Tevimbra (tislelizumab-jsgr) • ociperlimab (BGB-A1217)
    over1year
    AdvanTIG-206: Phase II randomized open-label study of ociperlimab (OCI) + tislelizumab (TIS) + BAT1706 (bevacizumab biosimilar) versus TIS + BAT1706 in patients (pts) with advanced hepatocellular carcinoma (HCC) (ESMO 2023)
    No new safety signals were identified in either arm. The OS data are premature and need further follow-up.
    Clinical • P2 data • Metastases
    |
    TIGIT (T Cell Immunoreceptor With Ig And ITIM Domains 2)
    |
    Tevimbra (tislelizumab-jsgr) • Avzivi (bevacizumab-tnjn) • ociperlimab (BGB-A1217)
    over1year
    AdvanTIG-306: Study of Efficacy and Safety of Ociperlimab in Combination With Tislelizumab and Platinum-based Doublet Chemotherapy as First-line Treatment for Participants With Locally Advanced or Metastatic NSCLC. (clinicaltrials.gov)
    P3, N=0, Withdrawn, Novartis Pharmaceuticals | N=980 --> 0 | Not yet recruiting --> Withdrawn
    Enrollment change • Trial withdrawal • Combination therapy • IO biomarker • Metastases
    |
    PD-L1 (Programmed death ligand 1)
    |
    PD-L1 expression
    |
    Keytruda (pembrolizumab) • cisplatin • carboplatin • Tevimbra (tislelizumab-jsgr) • albumin-bound paclitaxel • pemetrexed • ociperlimab (BGB-A1217)
    over1year
    AdvanTIG-211: Phase II Study Evaluating the Efficacy and Safety of Ociperlimab in Combination With Tislelizumab and Chemotherapy as First-line Treatment for Participants With Advanced Triple Negative Breast Cancer (clinicaltrials.gov)
    P2; N=250 --> 0 | Not yet recruiting --> Withdrawn
    Combination therapy • Enrollment change • Trial withdrawal • Metastases
    |
    PD-L1 (Programmed death ligand 1)
    |
    PD-L1 expression
    |
    PD-L1 IHC 22C3 pharmDx
    |
    Keytruda (pembrolizumab) • carboplatin • gemcitabine • Tevimbra (tislelizumab-jsgr) • albumin-bound paclitaxel • ociperlimab (BGB-A1217)
    over1year
    AdvanTIG-206: A Study Investigating the Efficacy and Safety of Ociperlimab and Tislelizumab and BAT1706 Combinations in Patients With Advanced HCC (clinicaltrials.gov)
    P2, N=90, Active, not recruiting, BeiGene | Trial primary completion date: Mar 2023 --> Aug 2023
    Trial primary completion date • Combination therapy • Metastases
    |
    PD-L1 (Programmed death ligand 1)
    |
    PD-L1 expression
    |
    Tevimbra (tislelizumab-jsgr) • Avzivi (bevacizumab-tnjn) • ociperlimab (BGB-A1217)
    over1year
    BGB-A317-A1217-202: AdvanTIG-202: Anti-PD-1 Monoclonal Antibody Tislelizumab (BGB-A317) Combined With or Without Anti-TIGIT Monoclonal Antibody Ociperlimab (BGB-A1217) in Participants With Previously Treated Recurrent or Metastatic Cervical Cancer (clinicaltrials.gov)
    P2, N=178, Active, not recruiting, BeiGene | Trial completion date: Mar 2023 --> Sep 2023
    Trial completion date • Metastases
    |
    PD-L1 (Programmed death ligand 1)
    |
    PD-L1 expression
    |
    Tevimbra (tislelizumab-jsgr) • ociperlimab (BGB-A1217)
    over1year
    AdvanTIG-211: Phase II Study Evaluating the Efficacy and Safety of Ociperlimab in Combination With Tislelizumab and Chemotherapy as First-line Treatment for Participants With Advanced Triple Negative Breast Cancer (clinicaltrials.gov)
    P2; N=250; Not yet recruiting; Sponsor:Novartis Pharmaceuticals
    Combination therapy • New P2 trial • Metastases
    |
    PD-L1 (Programmed death ligand 1)
    |
    PD-L1 expression
    |
    PD-L1 IHC 22C3 pharmDx
    |
    Keytruda (pembrolizumab) • carboplatin • gemcitabine • Tevimbra (tislelizumab-jsgr) • albumin-bound paclitaxel • ociperlimab (BGB-A1217)
    over1year
    AdvanTIG-306: Study of Efficacy and Safety of Ociperlimab in Combination With Tislelizumab and Platinum-based Doublet Chemotherapy as First-line Treatment for Participants With Locally Advanced or Metastatic NSCLC. (clinicaltrials.gov)
    P3, N=980, Not yet recruiting, Novartis Pharmaceuticals
    New P3 trial • Combination therapy • IO biomarker • Metastases
    |
    PD-L1 (Programmed death ligand 1)
    |
    PD-L1 expression
    |
    Keytruda (pembrolizumab) • cisplatin • carboplatin • Tevimbra (tislelizumab-jsgr) • albumin-bound paclitaxel • pemetrexed • ociperlimab (BGB-A1217)
    over1year
    BGB-A317-A1217-301: A Study to Compare Ociperlimab Plus Tislelizumab Versus Durvalumab Following Concurrent Chemoradiotherapy (cCRT) in Patients With Stage III Unresectable Non-Small Cell Lung Cancer (clinicaltrials.gov)
    P3, N=700, Recruiting, BeiGene | Trial completion date: Sep 2025 --> Jul 2027 | Trial primary completion date: Jan 2025 --> Feb 2027
    Trial completion date • Trial primary completion date • IO biomarker • Metastases
    |
    PD-L1 (Programmed death ligand 1) • TIGIT (T Cell Immunoreceptor With Ig And ITIM Domains 2)
    |
    PD-L1 expression
    |
    Imfinzi (durvalumab) • Tevimbra (tislelizumab-jsgr) • ociperlimab (BGB-A1217)
    almost2years
    Efficacy, Safety, and Pharmacodynamics of Tislelizumab Monotherapy and Multiple Tislelizumab-based Immunotherapy Combinations in Participants With Resectable Non-Small Cell Lung Cancer (clinicaltrials.gov)
    P2, N=90, Recruiting, BeiGene | Not yet recruiting --> Recruiting
    Enrollment open
    |
    PD-L1 (Programmed death ligand 1)
    |
    PD-L1 expression
    |
    Tevimbra (tislelizumab-jsgr) • ociperlimab (BGB-A1217) • LBL-007